Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERT-K: Ezetimibe/Rosuvastatin and Candesartan/Amlodipine in Hypertension and Hyperlipidemia
NCT03847506Phase 4Completed
- Sponsor
- HK inno.N Corporation
- Start
- Jul 2018
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ezetimibe, rosuvastatin, candesartan cilexetil and amlodipine in hypertension (HTN) and hyperlipidemia (3 arms), sponsored by HK inno.N Corporation. Primary endpoints: Change in sitting Systolic Blood Pressure at 6 weeks and Percentage change in LDL-C levels at 6 weeks. Started Jul 2018; status: completed.
02
Drugs
ezetimiberosuvastatincandesartan cilexetilamlodipine
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT03847506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847506.